Major advances in the first-line therapy of inoperable malignant pleural mesothelioma have occurred in the past 5 years. This Review summarizes evidence supporting the clinical activity of chemotherapy, discusses the use of end points for its assessment, and the influence of clinical and biochemical prognostic factors on the natural history of malignant pleural mesothelioma.
- Dean A Fennell
- Giovanni Gaudino
- Jan van Meerbeeck